Contents

Current Pharmaceutical Biotechnology, Volume 13 - Number 8

Editorial [Hot Topic: New Frontiers in Immunology and Infectious Diseases (Guest Editor: Stefan Borgmann)]

, 13(8): 1377

Stefan Borgmann


DOI: 10.2174/138920112800784934




Dendritic Cells: Elegant Arbiters in Human Reproduction

, 13(8): 1378 - 1384

Sabine E. Segerer, Claudia Staib, Ulrike Kaemmerer, Torsten Frambach, Arnd Honig, Johannes Dietl and Lorenz Rieger


DOI: 10.2174/138920112800784916




Monoclonal Antibodies for the Immunotherapy of Solid Tumours

, 13(8): 1385 - 1398

Richard Mauerer and Rudolf Gruber


DOI: 10.2174/138920112800784844




Clinical Experience with Gene Therapy and Bispecific Antibodies for T Cell-based Therapy of Cancer

, 13(8): 1399 - 1408

Patrick A. Baeuerle and Christian Itin


DOI: 10.2174/138920112800785005




Current Immunotherapy of Multiple Sclerosis and Future Challenges: Relevance of Immune-Mediated Repair

, 13(8): 1409 - 1417

Michael D. Carrithers


DOI: 10.2174/138920112800784781




Infections in Patients with Rheumatic Diseases Treated with TNF Antagonists

, 13(8): 1418 - 1425

Beatriz Perez-Zafrilla, Loreto Carmona and Juan J. Gomez-Reino


DOI: 10.2174/138920112800784808




The Intrinsic Apoptosis Pathways as a Target in Anticancer Therapy

, 13(8): 1426 - 1438

Verena Jendrossek


DOI: 10.2174/138920112800784989




Recent Advances in Active Specific Cancer Vaccine Treatment for Colorectal Cancer

, 13(8): 1439 - 1445

Kiyotaka Okuno, Fumiaki Sugiura, Kyogo Itoh, Koji Yoshida, Takuya Tsunoda and Yusuke Nakamura


DOI: 10.2174/138920112800784998




Bacteria and their Toxins Tamed for Immunotherapy

, 13(8): 1446 - 1473

Irena Adkins, Jana Holubova, Martina Kosova and Lenka Sadilkova


DOI: 10.2174/138920112800784835




Editorial [Hot Topic: New Treatment Strategies in Schizophrenia Beyond Dopamine: Glutamatergic Neurotransmission and More (Guest Editor: Christoph Mulert & Elizabeth Scarr)]

, 13(8): 1474 - 1475

C. Mulert


DOI: 10.2174/138920112800784871




Pharmacotherapy of Schizophrenic Patients: Achievements, Unsolved Needs, Future Research Necessities

, 13(8): 1476 - 1489

Hans-Jurgen Moller


DOI: 10.2174/138920112800784907




Subjective Well-being of Patients with Schizophrenia as a Target of Drug Treatment

, 13(8): 1490 - 1499

E. Karamatskos, C. Mulert, M. Lambert and D. Naber


DOI: 10.2174/138920112800784862




The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development

, 13(8): 1500 - 1512

Alice Egerton and James M. Stone


DOI: 10.2174/138920112800784961




DTNBP1 (Dysbindin) Gene Variants: In Vivo Evidence for Effects on Hippocampal Glutamate Status

, 13(8): 1513 - 1521

C. Wirth, F. Schubert, M. Lautenschlager, R. Bruhl, A. Klar, T. Majic, U. E. Lang, A. Ehrlich, G. Winterer, T. Sander, M. Schouler-Ocak and J. Gallinat


DOI: 10.2174/138920112800784952




Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Treatments

, 13(8): 1522 - 1534

L. J. Gray, A. J. Hannan and X. Zhang


DOI: 10.2174/138920112800784817




Recent Advances in Targeting the Ionotropic Glutamate Receptors in Treating Schizophrenia

, 13(8): 1535 - 1542

Robert E. McCullumsmith, John Hammond, Adam Funk and James H. Meador-Woodruff


DOI: 10.2174/138920112800784899




From Glutamatergic Dysfunction to Cognitive Impairment: Boundaries in the Therapeutic of the Schizophrenia

, 13(8): 1543 - 1548

P. A. Gaspar, M. L. Bustamante, L. E. Rojo and A. Martinez


DOI: 10.2174/138920112800784790




Disturbed Function of GABAergic Interneurons in Schizophrenia: Relevance for Medical Treatment?

, 13(8): 1549 - 1556

J. Genius, I. Giegling, J. Benninghoff and D. Rujescu


DOI: 10.2174/138920112800784943




Altered Cortical GABA Neurotransmission in Schizophrenia: Insights into Novel Therapeutic Strategies

, 13(8): 1557 - 1562

Ana D. Stan and David A. Lewis


DOI: 10.2174/138920112800784925




Selective Activation of Muscarinic Acetylcholine Receptors for the Treatment of Schizophrenia

, 13(8): 1563 - 1571

B. Dean


DOI: 10.2174/138920112800784970




Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in Schizophrenia

, 13(8): 1572 - 1586

H. Y. Meltzer, B. W. Massey and M. Horiguchi


DOI: 10.2174/138920112800784880




Treating Impaired Cognition in Schizophrenia

, 13(8): 1587 - 1594

H. M. Ibrahim and C. A. Tamminga


DOI: 10.2174/138920112800784772




Innovative Treatment Approaches in Schizophrenia Enhancing Neuroplasticity: Aerobic Exercise, Erythropoetin and Repetitive Transcranial Magnetic Stimulation

, 13(8): 1595 - 1605

T. Wobrock, A. Hasan and P. Falkai


DOI: 10.2174/138920112800784763




Immunological Treatment Options for Schizophrenia

, 13(8): 1606 - 1613

Norbert Muller, Aye-Mu Myint and Markus J. Schwarz


DOI: 10.2174/138920112800784826




Current Progress in the Genetic Research of Schizophrenia: Relevance for Drug Discovery?

, 13(8): 1614 - 1621

Dan Rujescu, Just Genius, Jens Benninghoff and Ina Giegling


DOI: 10.2174/138920112800784754




Functional Magnetic Resonance Imaging and Treatment Strategies in Schizophrenia

, 13(8): 1622 - 1629

Susanne Karch, Oliver Pogarell and Christoph Mulert


DOI: 10.2174/138920112800784853




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science